The novel oral SERD outperformed standard therapy in patients with ER-positive/HER2-negative metastatic and locally advanced breast cancers and a known drug-resistant gene mutation
The U.S. Food and Drug Administration (FDA) just approved giredestrant (Wilserdly) for treating estrogen receptor (ER)‑positive/HER2-negative locally advanced or metastatic breast cancer in patients with a known drug resistant gene mutation, ESR1.
ER-positive breast cancer makes up roughly 70% of all breast cancers. While endocrine therapy has been successful in treating this cancer type, some tumors become resistant to the therapy. Patients with ER-positive/HER2-negative breast cancer now have a new treatment option with the FDA-approval of giredestrant (Wilserdly).
Key Takeaways
- Giredestrant is the first next‑generation oral SERD to outperform standard endocrine therapy for ER‑positive/HER2-negative locally advanced or metastatic breast cancer in patients with a known drug resistance mutation in the ESR1 gene.
- In combination with another drug, everolimus, giredestrant delayed disease progression or death by 62% compared to standard endocrine therapy.
- ESR1 mutations drive endocrine therapy resistance in up to 40% of HR‑positive metastatic breast cancers—the new combination addresses resistance.
- Breast Cancer Research Foundation investigators played a key role in the research that helped lead to giredestrant’s FDA approval.
Giredestrant is a next-generation oral selective estrogen receptor degrader (SERD) and the first to significantly outperform standard endocrine therapy in certain breast cancers. The first-in-class SERD plus everolimus (Afinitor), an mTOR inhibitor, outperformed standard endocrine therapy plus everolimus in this population: Median progression free survival (PFS) was 10 months with giredestrant compared to 5.5 months with standard endocrine therapy (exemestane, fulvestrant, or tamoxifen).
FDA approval was based on the evERA breast cancer study.
What the data shows
Several Breast Cancer Research Foundation (BCRF) investigators were part of the evERA study team that conducted a phase 3, multi-center clinical trial (NCT05306340) testing giredestrant. Patients with ER‑positive/HER2‑negative locally advanced or metastatic breast cancer who were previously treated with endocrine therapy and CDK4/6 inhibitors took either giredestrant plus everolimus, or standard endocrine therapy plus everolimus. BCRF researchers involved in the study included Drs. Hope Rugo, Sara Tolaney, Komal Jhaveri, and William Gradishar.
The median progression free survival (PFS) was 8.8 months with the giredestrant and everolimus combination versus 5.5 months with standard endocrine therapy plus everolimus. In ESR1-mutated tumors, the numbers were even better: Median progression free survival was 10 months in those that took giredestrant versus 5.5 months with standard endocrine therapy, representing a 62% decrease in the risk of breast cancer progression or death.
Over 50% of the patients had ESR1-mutated tumors as determined by liquid biopsy with the FoundationOne Liquid CDx test. This test was also FDA authorized as a companion diagnostic, meaning that the liquid biopsy test can detect circulating tumor DNA (ctDNA) containing ESR1 mutations, identifying patients that would most benefit from treatment with giredestrant in combination with everolimus.
ESR1 mutations can develop during the course of treatment with endocrine therapy and CDK4/6 inhibitors. This is thought to drive tumor resistance since ESR1 mutations change the ER (estrogen receptor) so they can continue to grow even without estrogen. That makes the receptor partially resistant to ER-targeted treatments, which disrupt ER and estrogen binding. But giredestrant can maintain its efficacy even as the ER develops an ESR1 mutation—this is because as a SERD, giredestrant can still recognize the estrogen receptor and tag it to be broken down.
Notably, the results from evERA demonstrate that an all-pill regimen is effective for treating ER‑positive/HER2‑negative breast cancer in the metastatic setting.
There are potential side effects of the medication, as is the case with many cancer treatments. The most common in patients receiving giredestrant plus everolimus were rash, fatigue, diarrhea, musculoskeletal pain, nausea, inflammation of lung tissue, and inflammation in the tissue lining the mouth.
The evERA study demonstrates that the drug combination offers an improvement in disease management for ER-positive advanced breast cancer, particularly in those with ESR1 mutations. This marks a significant advancement in post‑CDK4/6 inhibitor treatment strategies.
What this means for patients
ER-positive/HER2-negative breast cancer is the most common type, making up about 70% of all breast cancers. With this approval, this large patient population has not only more options, but an all-pill option that significantly outperforms standard of care and is particularly effective when resistance to standard of care treatments develops. In addition, ESR1-mutated tumors can be detected by liquid biopsy, a simple blood draw, giving clinicians a way to identify those where the combination would be most beneficial.
An FDA approval for giredestrant in early‑stage ER‑positive breast cancer is expected this month. This would mark the first approval for a SERD in both adjuvant and advanced ER‑positive disease.
As the largest private funder of breast cancer research and metastatic breast cancer research in the world, this advancement shows the impact research has on patients’ lives. Donate to help fund today’s research that will lead to tomorrow’s cures here.